Confirming this, a large series analysis of non-V600 BRAF-mutant CRC patients receiving anti-EGFR therapy revealed that patients with class 3 BRAF mutations responded to anti-EGFR therapy, while those with class 2 BRAF mutations did not responded (29). This evidence concerns the gene EGFR and colorectal carcinoma.